Overview

Tarceva Italian Lung Optimization tRial

Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the superiority of docetaxel in comparison to erlotinib in second line in wild-type EGFR tumour patients.
Phase:
Phase 3
Details
Lead Sponsor:
Fatebenefratelli and Ophthalmic Hospital
Collaborators:
Mario Negri Institute for Pharmacological Research
Niguarda Hospital
Treatments:
Docetaxel
Erlotinib Hydrochloride